Famotidine is a competitive, reversible histamine H2-receptor antagonist. It is a potent antisecretory agent that significantly inhibits both basal and stimulated gastric acid secretion (including nocturnal and meal-stimulated secretion). It is widely used in the management of acid-peptic disorders. In the Indian context, it is a first-line and cost-effective therapy for GERD and ulcer management, though its use has been partially superseded by Proton Pump Inhibitors (PPIs) for certain conditions.
Adult: Duodenal/Gastric Ulcer: 40mg once daily at bedtime or 20mg twice daily for 4-8 weeks. GERD: 20-40mg twice daily for up to 12 weeks. Maintenance: 20mg once daily. Hypersecretory Conditions: 20-160mg every 6 hours, adjust to patient response.
Note: Oral: Can be taken with or without food. If taken once daily, best at bedtime for nocturnal acid control. Tablet should be swallowed whole with a glass of water. Do not crush/chew (unless a dispersible formulation). IV: For hospital use only, administered as slow IV injection or infusion.
Famotidine competitively and reversibly inhibits the action of histamine at the histamine H2 receptors located primarily on the parietal cells of the gastric mucosa. This blockade prevents the activation of adenylate cyclase, leading to a decrease in intracellular cyclic AMP (cAMP). Reduced cAMP levels inhibit the activation of the proton pump (H+/K+ ATPase), resulting in a profound reduction in both the volume and hydrogen ion concentration of gastric acid secretion.
Pregnancy: Category B: Animal studies have shown no risk, but adequate and well-controlled studies in pregnant women are lacking. Use only if clearly needed. Considered relatively safe for short-term use.
Driving: May cause dizziness or somnolence in some patients. Patients should not drive or operate machinery until they know how the drug affects them.
| Ketoconazole, Itraconazole, Atazanavir | Famotidine increases gastric pH, which can significantly decrease the absorption of these pH-dependent drugs, reducing their efficacy. | Major |
| Antacids | Concomitant administration may decrease the absorption of Famotidine. A gap of 1-2 hours is recommended. | Moderate |
| Warfarin | Theoretical interaction due to altered absorption; however, clinically significant interaction is rare. Monitoring of INR is still advised. | Minor |
| Procainamide | Famotidine may reduce renal clearance of procainamide, potentially increasing its plasma levels and risk of toxicity. | Moderate |
| Sucralfate | May bind to Famotidine in the GI tract, reducing its bioavailability. Administer Famotidine at least 2 hours before sucralfate. | Moderate |
Same composition (Famotidine (40mg)), different brands: